Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p274
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 274/312)
Character Range: 17186845–17193847

hospital who is either: (i) an endocrinologist, (ii) an oncologist; or
                                                                                                                           Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types within a hospital setting; AND
                                                                                                                           The condition must be active; AND
                                                                                                                           Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND
                                                                                                                           The treatment must be after failure of other therapy including dopamine agonists; or
                                                                                                                           The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
                                                                                                                           The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND
                                                                                                                           The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND
                                                                                                                           The treatment must cease if IGF1 is not lower after 3 months of treatment; AND
                                                                                                                           The treatment must not be given concomitantly with PBS-subsidised pegvisomant.
                                                                                                                           In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.
C16029              P16029         CN16029          Cefazolin                                                              Septicaemia, proven
                                                                                                                           Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
                                                    Cefotaxime

                                                    Ceftriaxone

C16030              P16030         CN16030          Cefazolin                                                              Septicaemia, suspected
                                                                                                                           Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
                                                    Cefotaxime

                                                    Ceftriaxone

C16034              P16034         CN16034          Fluconazole                                                            Fungal infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 16034
                                                                                                                           The condition must be serious or life-threatening; AND
                                                                                                                           Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16035              P16035         CN16035          Itraconazole                                                           Systemic histoplasmosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 16035
                                                                                                                           Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the